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Coronary artery disease and coronary artery bypass grafting  
Coronary artery disease is the predominant cause of cardiovascular disease, which is the 
leading cause of death worldwide1. The number of affected individuals is expected to rise 
further in the coming years due to changing lifestyles in the developing world2. Coronary 
artery disease refers to a spectrum of clinical conditions in which the pathophysiology is 
impaired supply of oxygenated blood to the myocardium, usually caused by atherosclerotic or 
thrombotic narrowing of the coronary arteries. Treatment aims to prolong survival, relieve 
symptoms of ischemia, improve functional status and thereby improve quality of life3. This 
may be achieved by optimal medication and, for selected groups of patients, by percutaneous 
coronary intervention (PCI) or coronary artery bypass grafting (CABG).  
      The Russian surgeon Vasilii Kolessov in 1964 performed the first sutured bypass 
grafting using the internal mammary artery without use of cardiopulmonary bypass4. The 
CABG procedure as we know today developed rapidly in the USA during the next years and 
surgical revascularization went from being experimental to become a standard treatment 
option for coronary artery disease. This was largely aided by the development of 
cardiopulmonary bypass and the angiography technique5. Further advances in coronary 
surgery, among them better myocardial preservation, use of arterial conduits and improved 
postoperative care, have reduced mortality and morbidity despite increasing age and greater 
co-morbidities in patients undergoing surgical revascularization6-9. Today, CABG is the most 
common type of cardiac surgery for adults, with more than 400,000 operations per year in the 
United States alone10. In Norway this number averages more than 2,300 procedures annually, 
which constitutes approximately 55% of all open-heart surgery procedures11. 
      In 1977 PCI was developed as a non-surgical alternative to CABG and has since been 
increasing in popularity12,13. A recent study reported that PCI rates in the United States were 
stable in the period 2001-2008, but the rates of CABG substantially declined during this time 
period. The indications for CABG versus PCI have long been an issue of debate due to few 
randomized trials and the evolution of drug-eluting stents showing promising results. To 
address this issue, the SYNTAX (Synergy between PCI with Taxus and Cardiac Surgery) 
study was conducted. This prospective randomized trial concluded that CABG remains the 
standard of care for patients with previously untreated three-vessel or left main coronary 
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artery disease14. These findings were important to re-emphasize the role of CABG as the 
evidence-based treatment of choice for these patient groups15.  
 
Myocardial stunning and hibernation 
Myocardial ischemia occurs when there is an imbalance between myocardial oxygen supply 
and demand, and this is usually a result of atherosclerosis. As the coronary artery lumen 
gradually narrows, blood flow is reduced and a myocardial adaption to ischemia evolves. 
Perfusion and contractile function seem to be matched, and consequently, if the ischemia 
continues, this may result in reduced contractile function16,17. If contributions from collaterals, 
plaque morphology, and abnormal microvasculature are ignored, coronary stenosis below 
approximately 40 percent will not influence blood flow18,19. Between approximately 40 and 
80 percent stenosis, resting myocardial blood flow will remain normal whilst maximum blood 
flow will be reduced. Thus, episodes of increased oxygen demand may result in a limited 
period of reversible left ventricular dysfunction, also characterized as myocardial stunning. A 
stenosis exceeding 80 percent of the vessel lumen may be associated with reduced resting 
blood flow and consequently reduced left ventricular contraction through perfusion-
contraction matching. As defined by Rahimtoola, hibernating myocardium is a condition of 
persistently impaired myocardial function at rest due to chronically reduced blood flow20. If 
the myocardial oxygen/demand relationship is favorably altered, left ventricular function may 
be partially or completely restored. Both myocardial stunning and hibernation share several 
common features, and there may be considerable overlap between the two states21. Possibly, 
they reflect a continuum, for example, repetitive stunning may contribute to the development 
of myocardial hibernation 22,23.  
       The aim of revascularization is to restore myocardial oxygen supply to the 
myocardium and thereby reduce symptoms of myocardial ischemia. Patients with 
dysfunctional, but viable, myocardium may additionally regain regional and global contractile 
function after revascularization24. However, the time course of improvement in myocardial 
function after CABG is not fully described. In patients with viable myocardium, the time 
needed to recover left ventricular function is quite variable and may take weeks, months or 
even more than a year25-28. Especially the early changes after revascularization, during the 
first days and weeks postoperatively, have been insufficiently documented. 
Several methods are available for detecting changes in myocardial perfusion and 
function. Myocardial perfusion scintigraphy, using radionuclide tracers, is a well-established 
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noninvasive method of evaluating coronary blood flow29,30. Echocardiography is a widely 
used diagnostic tool for evaluating myocardial function. It has the advantage of being 
noninvasive, widely available and inexpensive, but is limited by being dependent on the 
examiner`s experience31.  
 
Diagnosis of perioperative myocardial infarction 
Perioperative myocardial infarction is a complication of CABG and an important cause of 
postoperative mortality32,33. The incidence of perioperative myocardial infarction varies in the 
literature and has been reported ranging from 1.3 % to 25% in different populations34-36. The 
diagnosis can be difficult to make after CABG since release of myocardial biochemical 
markers caused by direct surgical manipulation, global ischemia or inadequate myocardial 
protection is common37 and may be difficult to distinguish from myocardial damage owing to 
an acute infarction. New Q-waves in the ECG have been considered the most reliable 
diagnostic measure, yet, their clinical relevance for prognosis has also been questioned38,39. 
The Joint Task Force of the European Society of Cardiology/American College of Cardiology 
in 2007 defined a CABG related myocardial infarction as a biomarker elevation > 5 times the 
upper limit of normal within the first 72 hours postoperatively when associated with the 
appearance of new pathological Q-waves or new left bundle branch block, or angiographically 
documented new graft or native coronary artery occlusion, or imaging evidence of new loss of 
viable myocardium40. However, the cut-off chosen for biomarker elevation lacks supportive 
evidence, and these recommendations have been an issue of debate40,41.  
 
Left ventricular hypertrophy and albuminuria 
Left ventricular hypertrophy (LVH), determined by the Cornell voltage product or Sokolow-
Lyon voltage in the ECG or by echocardiography, is an independent predictor of 
cardiovascular morbidity and mortality42-44. A study by Liao et al45 found that LVH was 
associated with a greater risk of all-cause mortality than coronary artery single-vessel or 
multivessel-disease verified by coronary angiography or left ventricular systolic dysfunction. 
The exact pathophysiological mechanisms are unknown, but may involve systemic 
inflammation, atherosclerosis, endothelial dysfunction and direct myocardial alterations. LVH 
has been associated with coronary artery calcium and carotid plaque46-48, supporting that LVH 
is associated with subclinical atherosclerosis.  
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      The urine albumin-to-creatinine ratio is a measure of endothelial damage at the 
glomerulus, reflecting early dysfunction in the vascular tree in general49. It has been related to 
subclinical atherosclerosis in the general population50,51 as well as in hypertensive patients52. 
Regression of left ventricular hypertrophy and albuminuria during antihypertensive treatment 
is shown to reduce the risk of cardiovascular events53,54. However, the effect of regression of 
LVH and albuminuria regarding the end point revascularization has not been studied, despite 
the fact that several studies link these two risk factors with atherosclerosis48,51.  
  
Biochemical markers of survival after CABG 
Elevations of creatine kinase myocardial-band (CK-MB) and cardiac troponins are common 
after CABG. CK-MB is an isoenzyme of creatine kinase which is located in the cytosol and 
mainly expressed in the myocardium55. Troponin is a protein complex of three subunits (T, I 
and C) that modulates the calcium-mediated interaction between actin and myosin in skeletal 
and cardiac muscle tissue56. As cardiac troponins are the most sensitive and specific among 
the cardiac biomarkers, they are regarded as “the gold standard” for diagnosing acute 
coronary syndromes40. When it comes to biomarkers post-CABG, both CK-MB and troponins 
have been associated with short- and mid-term mortality57-60, but their long-term prognostic 
value remains unclear. Furthermore, few studies have compared the prognostic effects of CK-






Aims of the thesis  
 
 
Paper I  To test the hypothesis that myocardial perfusion scintigraphy may elucidate 
myocardial perfusion and ischaemia associated with CABG. To test the 
hypothesis that myocardial perfusion scintigraphy can detect more cases of 
perioperative myocardial infarction after CABG than cardiac biochemical 
markers and ECG. 
 
Paper II To test the hypothesis that left ventricular function improves during the first 
seven weeks postoperatively after CABG.  
 
Paper III To test the hypothesis that regression of left ventricular hypertrophy (LVH) and 
urine albumin-to-creatinine ratio is associated with the incidences of coronary 
and peripheral revascularization in hypertensive patients and to test whether 
regression of LVH after completed coronary or peripheral revascularization 
reduces cardiovascular mortality.  
 
Paper IV To test the hypothesis that CK-MB and cTnT are predictors of long-term 
mortality after CABG and to determine which of these two biochemical 




Materials and methods 
 
Papers I and II 
Patient population  
113 patients scheduled for first-time elective CABG at Oslo University Hospital, Ullevål were 
included in the prospective SCENARIO (SCintigraphic EvaluatioN of Aortacoronary 
Revascularization Inhospital Organization) study from January 2002 to August 2003. The 
indication for operation was symptomatic coronary artery disease with at least one significant 
coronary artery stenosis (>50% lumen diameter reduction) determined by angiography, not 
suitable for PCI. The pre-specified exclusion criteria were combined procedures, renal failure, 
chronic obstructive pulmonary disease, body mass index > 30 kg/m2 and age above 80 years. 
The research protocol was approved by the Regional Ethics Committee of Eastern Norway. 
All patients gave verbal and written informed consent.  
      Patients were at inclusion randomized consecutively into two groups; a study group 
and a control group (Figure 1). Randomization was performed by drawing sealed envelopes. 
All included patients underwent standard CABG surgery and standard postoperative care at 
our hospital. Daily ECGs and cardiac biochemical markers at 7, 20, 44 and 72 hours 
postoperatively were registered for all patients. The study group additionally underwent 
myocardial perfusion scintigraphy and echocardiography at rest 1-7 days preoperatively, 2-4 
days postoperatively and 6-7 weeks postoperatively. Surgery was cancelled for seven patients 
and two patients withdrew their informed consent. Due to this fairly small, but uneven 
withdrawal rate, we had to re-randomize and continue inclusions, leaving a total of 102 
patients for analysis; 48 in the control group and 54 in the study group.  
       A few patients did not participate in all three examinations, either because of 
their clinical condition (pain, reduced mobility or postoperative confusion) or due to logistical 
reasons as the high turnover in the department resulted in rapid transferral of patients to their 
local hospitals. Therefore, data were presented both as data for all patients with at least one 
examination and as paired data for patients having a complete set of all three examinations 
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CABG with cardiopulmonary bypass was performed during moderate hypothermia (32-34°C) 
via median sternotomy. Myocardial revascularization was performed by a left internal 
mammary artery graft to the left anterior descending (LAD) coronary artery and saphenous 
vein bypass grafting to other diseased vessels. The distal anastomoses were completed first 
and the proximal anastomoses were completed after removal of the cross-clamp.   
 
Myocardial perfusion scintigraphy 
Patients were injected with 400-500 mega-bequerel (MBq) 99mTechnetium-tetrofosmin 
(99mTc) (Myoview¥, Amersham Health, Buckinghamshire, UK) at rest and given a light 
meal to accelerate hepatobiliary clearance. Thereafter, 32 projection images were acquired 
using a dual-head rotational gamma camera (Sophy DST, Sopha Medical Vision). Images 
were checked for patient motion and slice reconstruction was performed with standard filtered 
back projection technique by a technician blinded for clinical information, but not for time of 
examination. No attenuation- or scatter-correction was used. Data processing was performed 
by the use of a dedicated Sophy NXT computer system to produce short-axis, vertical and 
horizontal long-axis tomographic slices, and bull’s eye plot of the left ventricle. Based on the 
size and severity of the perfusion defect in the bull’s eye plot, the program calculated a 
hypoperfusion index. The hypoperfusion index was defined as the product of the defect extent 
(in percent of left ventricular surface) by its mean severity, expressed in percentage of the 
expected total heart uptake61. The best perfused area was defined as 100% radionuclide 







Definition of perioperative myocardial infarction 
In the control group, perioperative myocardial infarction was defined as CK-MB  70 ng/ml 
and/or cTnT  3.5 ng/ml and peak value on the first postoperative day and ECG changes. In 
the study group, the same definitions as in the control group were used and in addition, 
perioperative myocardial infarction was defined as an increase in the hypoperfusion index  5 
from the preoperative scintigraphic examination to the 2-4 days postoperative examination, 
with a fixed perfusion defect at the 6 weeks postoperative examination. 
 
Echocardiography 
Transthoracic two-dimensional echocardiography at rest was performed using a Vivid 5 
scanner (GE Vingmed, Horten, Norway), equipped with a 1.7 MHz transducer in the second 
harmonic mode. M-mode echocardiographic analysis was based on the criteria of the 
American Society of Echocardiography62. Volumes and left ventricular ejection fraction 
(LVEF) were calculated using Simpson`s biplane method. Four standard views of the left 
ventricle were digitally stored in EchoPAC (GE Vingmed, Horten, Norway) for subsequent 
off-line analysis; parasternal long- and short-axis views and apical two- and four-chamber 
views. Echocardiography was performed by an experienced cardiologist blinded for clinical 
data, but not for the time of surgery. The intra-observer variation coefficients for end-diastolic 
volume and ejection fraction were 6.5% and 9.5%, respectively63.  
 
Figure 2. Bull`s eye plot. 
A resting myocardial perfusion scintigram, bull`s eye 
plot, from one of the study patients preoperatively. The 
red colored area demonstrates normal radionuclide uptake 
(normal perfusion), whilst the green/yellow area 
anteroseptally demonstrates a region with reduced 
radionuclide uptake (reduced perfusion). The 




Regional wall motion was evaluated using a 16-segment model recommended by the 
American Society of Echocardiography64. The left ventricle was divided into six basal 
segments (anterior, anterolateral, inferolateral, inferior, inferoseptal and anteroseptal), six 
middle segments (same subgroups) and four apically located segments (anterior, septal, 
inferior and posterior). By visual analysis of systolic wall thickening, including in patients 
with abnormal septal motion after opening the pericardium during surgery, segments were 
assigned a wall motion score as follows: 1 = normal or hyperkinetic (normal endocardial 
excursion and systolic wall thickening), 2 = hypokinetic (reduced excursion and wall 
thickening), 3 = akinetic (absent excursion and wall thickening) and 4 = dyskinetic (paradoxic 
systolic outward wall motion). Wall motion score index (WMSI) was calculated by dividing 
the sum of all wall motion scores by the total number of segments analyzed. An improvement 




Figure 3. The 16 segment model.  
Illustration of the 16 segments left ventricular model with 
standardized segmentation and theoretical perfusion territories. In 
this patient, the sum of the wall motion scores of all segments was 
22, giving a WMSI of 22/16 = 1.38. The orange segments are 
generally perfused by the left anterior descending (LAD) artery, 
the blue segments are perfused by the right coronary artery (RCA) 
and the green segments are perfused by the circumflex (CX) 
artery. Modified after Grenne et al65.  
 
Myocardial biochemical markers 
Serum cTnT concentration and serum CK-MB concentration were determined by using 
electrochemiluminescence immunoassay (ECLIA) on the Roche Elecsys 2010 immunoassay 
analyzer (Roche Diagnostics, Mannheim, Germany) at the Department of Clinical Chemistry, 
Oslo University Hospital, Ullevål. The normal reference area for the cTnT test was 0-0.10 





A serial 12-lead ECG was recorded preoperatively and on the first, second and third 
postoperative day. The ECGs were evaluated using World Health Organization criteria66 by a 
cardiologist who was blinded for clinical data and had long experience in using these criteria. 
New Q-waves of ≥ 40ms duration or new QS-waves in multiple leads were considered more 
significant than ST-segment or T-wave changes, conduction disorders and new Q-waves in 
single leads.  
 
Statistics 
Statistical analysis was performed using SPSS versions 12.0 and 16.0 (SPSS, Chicago, IL, 
USA). Data are presented as mean ± standard deviation with range in parentheses for 
continuous variables with distribution sufficiently close to the normal distribution, median 
and 25th and 75th percentiles for continuous variables with distributions deviating markedly 
from the normal distribution, and proportions for categorical variables with percentages in 
parentheses. An exception was done for WMSI, which was presented as mean value despite 
being non-parametric. Normally distributed data were compared by Student t test. Non-
normally distributed data were compared by Mann-Whitney U test for independent samples 
and Wilcoxon signed ranks test for paired samples. In paper II Friedman`s test for repeated 
measures was used. Categorical variables were compared using Pearson`s chi-square test or 




Patient population  
The Losartan Intervention For Endpoint reduction in hypertension (LIFE) study prospectively 
included 9193 patients aged 55-80 years with previously untreated or treated essential 
hypertension (>160/90 mmHg) and electrocardiographic LVH. In double-blind fashion 
patients were randomized to a losartan- or atenolol-based regimen and treated to a target 
blood pressure of <140/90 mmHg. In all patients, urine albumin-to-creatinine ratio, LVH by 
electrocardiography, serum high-density lipoprotein (HDL) cholesterol, plasma glucose and 
blood pressure were measured after two weeks of placebo treatment and yearly during the 
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mean 4.8 years of anti-hypertensive treatment. All patients gave written informed consent, 
and the protocol was approved by regional ethical committees. 
      The revascularization analyses were a pre-specified part of the LIFE protocol with 
revascularization being a pre-specified secondary endpoint67. Each revascularization event 
was reported by the investigators and verified by an independent endpoint classification 
committee consisting of two cardiology experts and based on definitions in a pre-defined 
endpoint manual. Coronary revascularization was defined as all coronary artery 
revascularization procedures (angioplasty, atherectomy and stent) and heart transplants 
(which constituted very few, n<5). Peripheral revascularization included all non-coronary 
artery vascular surgeries and revascularization procedures (aortic aneurysm repair, carotid and 
peripheral revascularizations and amputations due to arterial vascular insufficiency and 
diabetes mellitus).  
 
Electrocardiography 
Standard 12-lead ECGs were taken at baseline, at six months and at yearly follow-up intervals 
until study termination or patient death. ECGs were interpreted by experienced readers 
blinded to clinical data at the Core Laboratory at Sahlgrenska University Hospital/Östra in 
Gothenburg, Sweden. LVH was defined as the product of QRS duration multiplied by the 
Cornell voltage combination (RaVL + SV3, with 6 mm added in women) higher than 2,440 mm 
x ms or Sokolow-Lyon voltage (SV1 + RV5/6) higher than 38 mm. 
 
 
                      
Figure 4. Diagnosis of LVH by the Sokolow-Lyon and Cornell product criteria. 
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Urine albumin-to-creatinine ratio 
Albuminuria was measured by standard methods using a turbidimetric method (Hitachi 717 
Analyser; Boehringer Mannheim, Mannheim, Germany) in a single spot urine collection on 
the morning of the baseline ECG and after 12 months. Both serum and urine creatinine were 
analyzed using the Jaffé reaction without deproteinizing and then quantified by a photo-metric 
method (Hitachi 717 Analyzer). The urine albumin concentration was expressed as a ratio to 
urinary creatinine concentration, to provide a composite measure of renal glomerular capillary 
permeability adjusting for urine dilution.  
 
Statistics 
Statistical analysis was performed using SPSS version 12.0. Continuous variables were 
compared using one-way analysis of variance (ANOVA) and Student t test. Categorical 
variables were compared using Pearson`s chi-square test. Cox regression analysis with time-
varying covariates was used in order to evaluate the importance of baseline as well as in-
treatment values through year five of treatment. After testing for linearity and the proportional 
hazard assumption and assessing the distribution of residuals from the models, urine albumin-
to-creatinine ratio was log-transformed in the analyses. Multiple Cox regression analyses 
were used to adjust for randomized treatment, continent (USA vs. European countries), 
Framingham risk score (including age, gender, total- and HDL cholesterol, systolic blood 
pressure, smoking, diabetes and LVH68) and known cardiovascular diseases as well as in-
treatment pulse pressure and in-treatment HDL cholesterol. Backward selection was used 
until all variables had P < 0.10, and these significant variables were included in the final 
models together with treatment and continent. In-treatment Sokolow-Lyon voltage and 
Cornell product were used both as continuous as well as dichotomous variables. Data were 
also analyzed using baseline and 1-year ECGs to predict revascularization after one year of 
treatment (excluding revascularization during the first year to avoid bias). In the time-varying 
analyses, however, all revascularization events were included. For all tests, two-tailed P < .05 





Patient population  
The study population consisted of all patients operated on consecutively for isolated CABG at 
Oslo University Hospital, Ullevål in the time period January 1, 2003 to December 31, 2006, 
which constituted 1350 patients in total. Patients undergoing additional surgery to CABG 
were excluded. The study was approved by an institutional review board. All patients 
underwent standard CABG operations and had routinely measurements of CK-MB and cTnT 
at 7 hours, 20 hours and 44 hours postoperatively. 
      The endpoint was all-cause mortality, and death status was assessed by the Norwegian 
National Death Registry by June 30, 2011 which gave a follow-up time of median 6.1 years. 
Data collection regarding death status was undertaken more than 3 months after this date to 
allow time for all deaths to be registered. A few patients had emigrated, and these were 
censored from the emigration date or date of last contact. Five patients were excluded because 
they could not be identified in the National Registry, and three were excluded because of 
missing postoperative blood samples. Thus, a total of 1,342 patients were eligible for further 
analysis. Of these, 1,294 had undergone elective surgery and 48 had undergone emergency 
surgery (3.6 %), based on the definition by European System for Cardiac Operative Risk 
Evaluation (EuroSCORE)69.  
 
Surgical procedure 
All patients underwent median sternotomy and were operated on using the standard technique 
of cardiopulmonary bypass with ascending aorta cannulation, single venous cannulation and 
moderate systemic hypothermia, as previously described in the methods section of papers I 
and II.  
 
Myocardial biochemical markers 
Serum cTnT concentration and serum CK-MB concentration were determined by using the 
third- or fourth-generation TnT test (Troponin T STAT) on the Roche Elecsys 2010 
immunoassay analyzer (Roche Diagnostics, Mannheim, Germany) according to the 
manufacturer recommendations. Serum CK-MB concentration was determined by using two 
monclonal antibiodies (CK-MB STAT) on an Elecsys 2010 analyzer (Roche Diagnostics) by 
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electrochemiluminescence immunoassay. The upper normal reference limit was 0.10 μg/Lfor 
cTnT and 5 μg/L for CK-MB.  
 
Statistics 
Data management and analysis were performed with IBM SPSS version 19.0 software. Mean 
values were compared using Student t test for normally distributed data and Mann-Whitney U 
test for non-parametric data. Categorical variables were compared using the chi-square test or 
Fisher`s exact test when appropriate. Event rates were calculated and plotted according to the 
Kaplan-Meier product limit method. The independence of the relationship of cTnT and CK-
MB to mortality was evaluated in Cox proportional hazards models. The proportional hazards 
assumption was verified by plotting log minus log of survival against survival times. All 
clinical relevant baseline and procedural variables were tested in Cox univariate analyses. 
Variables with a univariate P <.10 were included in the multivariate Cox model. Collinearity 
was checked by assessing the variance inflation factor, and a factor <5 was accepted. The 
variable EuroSCORE provided  a high variance inflation factor, and was thus excluded from 
the multivariate analysis with other clinical variables. The relationship of CK-MB to mortality 
was also evaluated in a multivariate Cox model with baseline variables, but not with cTnT as 
covariate. Furthermore, CK-MB and cTnT were analyzed separately and together in Cox 
models adjusting for EuroSCORE. There was no significant interaction between CK-MB and 




Summary of the results 
 
Paper I 
The hypoperfusion index, assessed by myocardial perfusion scintigraphy at rest, was 
significantly reduced from preoperatively to 2-4 days after CABG. This demonstrated an 
improvement in myocardial perfusion. There was no further change in the hypoperfusion 
index at 6 weeks postoperatively. Three patients (2.9%) were diagnosed with a perioperative 
myocardial infarction based on increases in cardiac biochemical markers and ECG changes. 
No additional cases of perioperative myocardial infarction were demonstrated by myocardial 
perfusion scintigraphy.  
 
Paper II 
Resting WMSI, assessed by echocardiography, was significantly reduced from preoperatively 
to 2-4 days after CABG. This demonstrated an improvement in contractile function. 
Furthermore, there was a borderline significant reduction in WMSI in the period between 2-4 
days postoperatively and 6-7 weeks postoperatively (p=0.06). 101 of 670 segments (15%) had 
abnormal contraction preoperatively; of which 69 were hypokinetic and 32 were akinetic. At 
6-7 weeks postoperatively a normalization in contractile function was found in 35 (51%) 
hypokinetic segments and a deterioration to akinesia was found in 5 segments. Nineteen 
(59%) of the akinetic segments had improved contractility at 6-7 weeks postoperatively.   
 
Paper III 
During the mean 4.8 years of follow-up in the LIFE study, 337 patients underwent coronary 
revascularization and 231 patients underwent peripheral revascularization. Higher Sokolow-
Lyon voltage, but not higher Cornell product or urine albumin-to-creatinine ratio, was 
associated with coronary and peripheral revascularization. Of the 568 patients who underwent 
either coronary or peripheral revascularization, 46 died of cardiovascular disease within the 
study period. There was no association between LVH defined by Sokolow-Lyon criteria and 
cardiovascular mortality after revascularization. In contrast, LVH defined by Cornell product 





One thousand three hundred fifty patients were followed for a median 6.1 years after CABG 
and during this period 207 patients (15.3%) died. Nearly all patients had elevated levels of 
cTnT and CK-MB postoperatively. Both peak CK-MB and peak cTnT independently 
predicted long-term all-cause mortality when analyzed in separate multivariate Cox regression 
models adjusting for baseline characteristics and perioperative variables. However, when 
analyzed together in the same Cox model, cTnT was a highly independent predictor, whereas 
CK-MB was nonsignificant. Cardiac Troponin T and CK-MB were also analyzed together in 
a model adjusting for EuroSCORE, and in this model cTnT, but not CK-MB, was a 
significant predictor of mortality. Strict quartile analysis of the two biomarkers gave the same 
results, with only quartiles of cTnT being significantly associated with long-term mortality. 
The biomarker value at 44 hours postoperatively had a stronger association with mortality 
than the biomarker values at 7 or 20 hours postoperatively or the peak value. 
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Discussion of materials and methods 
 
Papers I and II 
There were several reasons for choosing a randomized study design for the SCENARIO 
study. First, by adding a control group neither examined with myocardial perfusion 
scintigraphy nor echocardiography, we obtained a control to whether scintigraphy and 
echocardiography adds useful information beyond ECG and specific cardiac enzymes in 
detecting perioperative myocardial infarction. Second, as we had permissions (by hospital) to 
do scintigraphy in 50 patients, doubling the number of participants made it more likely that 
patients randomized to undergo scintigraphy and echocardiography were representative for 
the patients that qualified according to inclusion and exclusion criteria and underwent CABG 
at our hospital in the time period of the study. 
To study isolated CABG patients without combined valve surgery or other procedures 
was chosen to obtain a relatively homogenous study population undergoing the same type of 
cardiac surgery. Patients with renal failure, chronic obstructive pulmonary disease and age 
above 80 years were excluded as these patients may follow an extended and more 
complicated postoperative course with a higher tendency of respiratory problems and longer 
intensive care unit stay, which potentially could make it difficult to undergo the examinations 
at 2-4 days postoperatively. Also, chronic obstructive pulmonary disease may deliorate image 
quality obtained by echocardiography. Body mass index > 30 kg/m2 was initially chosen as an 
exclusion criteria because of the narrow examination bench used for the scintigraphy 
examinations. However, this turned out to be less a problem, and a few patients with higher 
body mass index were included after a subjective assessment. Due to the exclusion criteria, 
our study population was biased. It was therefore not representative of a typical elective first-
time CABG population and can be viewed as a best-case population of CABG-operated 
patients in our center. Hence, our results cannot be extrapolated to patients with co-
morbidities of chronic obstructory pulmonary disease or renal failure, age above 80 years or 
obesity. 
Including patients into such a study was quite cumbersome and as many as 261 
patients were not included because of exclusion criteria or logistical reasons. The logistical 
reasons were mainly due to unavailability of the study investigators to include patients and 
limited availability of myocardial perfusion scintigraphy in a busy clinical department.  
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To elucidate myocardial perfusion, myocardial perfusion scintigraphy at rest, which is 
a well-established noninvasive and safe technique for evaluating coronary perfusion, was 
undertaken70. Administration of nitroglycerin before the examination may increase coronary 
blood flow in ischemic myocardium, and thus facilitate radionuclide uptake in ischemic 
regions with viable myocytes71,72. This was not used in our study, but in retrospect we 
acknowledge that this might have limited the number and size of uptake defects. In addition, 
the use of gating would have enabled us to simultaneously evaluate left ventricular function73.  
All patients had ECGs taken routinely and these were copied and read by an 
experienced cardiologist. Electrocardiographic changes were classified based on ischemic 
severity, and we focused on the presence of new Q-waves in multiple leads for the diagnosis 
of perioperative myocardial infarction. Due to sternotomy bandages postoperatively, the 
electrodes were not always optimally placed and there may therefore be some minor day-to-
day variations. However, this was inevitable and reflects clinical practice.  
           As there was no consensus on the diagnosis of perioperative myocardial infarction 
after CABG when this study was designed, we had to make our own definitions based on 
available literature38,74. We chose to require both changes in biochemical markers and in the 
ECG for the diagnosis. We found no consensus regarding changes in the hypoperfusion index 
in the case of perioperative myocardial infarction. However, as an increase or reduction in the 
hypoperfusion index  5 in the same patient was considered a true change75, we chose this 
cut-off for the diagnosis of perioperative myocardial infarction determined by myocardial 
perfusion scintigraphy.   
      Our study population was unselected regarding preoperative left ventricular function. 
The preoperative echocardiography examination revealed a mean WMSI of 1.19 and 85% of 
the segments had normal contractility, demonstrating a relatively well-preserved function for 
the population as a whole. A normal contracting segment with a wall motion score of 1.00 
preoperatively cannot improve further in function. As a consequence, we might have 
experienced a greater improvement in contractile function if our study patients had been pre-
selected regarding low ejection fraction. Moreover, our patients were not pre-selected 
regarding image quality. Care was taken to obtain good images, however, image quality was 
variable and especially the 2-4 days postoperative examination may have been influenced by 
patient immobility and bandages. Wall motion scoring may be limited by dependence of the 
experience and the subjective interpretation of the observer. Yet, our patients were analyzed 





The LIFE study included a large population and was a multi-center trial, thereby 
strengthening the generalizability of our results. However,, it must be recognized that the 
LIFE population, as in many other randomized trials, had strict inclusion criteria and 
obviously represented a selected cohort of patients. Patients with angina pectoris requiring 
treatment with a beta-blocker or a calcium antagonist, severe vascular disease, heart failure, 
known LVEF < 40% or recent myocardial infarction within the past six months were 
excluded from this study. Hence, our results may not be representative of the typical 
hypertensive population undergoing revascularization, and this limits the external validity of 
the results. The LIFE study was designed for the primary composite endpoint, not for the 
secondary endpoints like revascularization. Our results from regression analysis should 
therefore be interpreted with caution as they demonstrate associations between variables and 
not necessarily imply a causal effect. Large randomized trials like the LIFE study are not 
designed to explain pathophysiological issues, but have an important role in generating 
hypotheses to be investigated in future prospective studies.  
      Revascularization procedures are based on several factors. In addition to being a 
consequence of arterial disease, revascularization is also a therapeutic intervention influenced 
by clinical decision-making. Therefore, it is not only a natural event, but a clinician-driven 
outcome influenced by physicians` decision-making based on individual preference and local 
availability as well as guideline recommendations76. The proportion of the patients 
undergoing coronary revascularization among the LIFE population was highest in the United 
States with 8.4% and ranged from 1.5 to 8.0% in European countries77. To account for these 
country-related differences in procedure rates, we adjusted the multivariate analyses for 
continent (US vs. Europe). The analyses were also adjusted for study drug treatment, as 
atenolol might worsen peripheral artery disease symptoms while it might weaken angina in 
comparison to losartan. 
 
Paper IV 
The study population consisted of all consecutive patients undergoing isolated CABG in our 
center during three years and was thus a heterogeneous cohort regarding co-morbidities, 
ejection fraction and operation risk. Including all patients was seen as an advantage because it 
increases the generalizability of our results to the clinical setting. We chose also to include the 
48 patients undergoing emergent surgery to avoid potential selection bias. All-cause mortality 
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was chosen as end-point as this is a strict and objective definition78. Since data were 
registered prospectively in a database, the variables encoded were pre-determined. Further 
information on postoperative outcomes, e.g., inotropic support and short-term complications 
would have been an advantage; however, the study design did not allow this. Available blood 
samples before operation were recorded, but these had been taken at variable times in the 
weeks or days before the operation and could therefore not give reliable information regarding 
the biomarker level preoperatively. Some patients with recent myocardial infarction may 
therefore have had elevated biochemical markers preoperatively that could contribute to the 
rise in biomarker levels postoperatively. The timing of the measurements of CK-MB and 
cTnT at 7, 20 and 44 hours postoperatively was according to the already established routine at 





Discussion of the results 
 
Paper I 
Improvement in hypoperfusion index after CABG 
The finding that CABG early postoperatively re-establishes myocardial blood flow may from 
a clinical point of view seem quite obvious. However, as the scintigraphic examinations were 
performed at rest, this was an interesting finding. Radionuclide uptake is a process requiring 
adequate perfusion and vital myocytes with intact cell membranes79,80. In a rest situation in 
which a patient has no symptoms of angina pectoris one would assume that perfusion would 
be adequate. Yet, our patients showed an improvement in radionuclide uptake at rest after 
CABG. Because radionuclide uptake requires vital myocytes, we believe that myocytes that 
appeared to be necrotic preoperatively actually may have been viable hibernating myocytes.  
      We found no change in hypoperfusion index between the two postoperative 
examinations at 2-4 days postoperatively and 6 weeks postoperatively. The improved 
radionuclide uptake within the myocytes therefore occurred relatively fast after 
revascularization. Other studies have revealed more gradual changes in myocardial perfusion, 
but comparisons with other studies are complicated by various methods of analyzing 
radionuclide uptake and different patient materials. Anderson et al81 reported that resting 
technetium-99m-sestamibi uptake defects were unchanged 1 hour after CABG, increased in 
severity after 1 week and were less than recorded preoperatively after one year. Raff et al82 
found that 16% of the hypoperfused segments at rest were improved during the first week 
after CABG. Several studies have documented improvements in resting perfusion with 
examinations at 3 months83,84 and 6 months85 after CABG.  
 
Diagnosis of perioperative myocardial infarction 
Using our definition requiring changes in cardiac biochemical markers and in the ECG, we 
found two patients with perioperative myocardial infarction in the control group and one 
patient in the study group. We had anticipated finding several patients fulfilling the criteria of 
perioperative myocardial infarction by myocardial perfusion scintigraphy; however, we 
detected none. Thus, a total of three patients (2.9%) were diagnosed with a perioperative 
myocardial infarction. This is a small number that does not allow further analysis and we 
could therefore not compare the incidences of perioperative mycoardial infarction in the two 
groups as originally planned. The finding that myocardial perfusion scintigraphy did not 
31 
 
detect more cases of infarction than ECG and biochemical markers, must be interpreted with 
caution. With our limited sample size it is likely that we did not find relationships that could 
have been detected studying a larger population (type II statistical error). Moreover, it is 
possible that we used too strict diagnostic criteria. Five patients had a significant increase in 
the hypoperfusion index between the two postoperative examinations, which may represent a 
new myocardial infarction or early graft failure. Unfortunately, our patients did not undergo 
coronary angiography postoperatively; which ultimately is the gold standard in diagnosing 




Improvement in WMSI after CABG 
As outlined in the introduction, the time course of recovery of left ventricular function in 
dysfunctioning myocardium after CABG has not been described in detail. Despite the 
relatively well-preserved contractile function in our study population preoperatively, we 
demonstrated improvement in resting WMSI postoperatively. This suggests present viability, 
due to the existence of (repetitively) stunned or hibernating myocardium. We found a gradual 
improvement of regional function during the seven weeks after CABG, indicating that the 
myocytes gradually resume their contractility several weeks after perfusion is restored. There 
was a significant improvement in function between preoperatively and 2-4 days 
postoperatively, in accordance with other studies86-88. A study by La Canna et al89 showed that 
regional wall motion score improved significantly immediately after CABG with no further 
improvement at 2 weeks or 3 months. Vanoverschelde et al25 found that patients with 
reversible dysfunction had improved wall motion score within 10 days postoperatively. Mintz 
et al90 reported no improvement in wall motion one week after CABG, but significant 
recovery at two months and one year postoperatively. Other studies have found no change91 or 
a deterioration of contractile function92 during the first weeks postoperatively, which may owe 
to perioperative ischemia, reperfusion injury or other factors that may have a negative effect 
on contractile function.  
       Only 101 segments (15%) in the study had abnormal contractile function 
preoperatively, which thereby limited the number of available segments for improvement 
after CABG. Sixty-nine of these (68%) were hypokinetic and the remaining were akinetic. 
The majority of both the hypokinetic and akinetic segments gradually improved in function 
during 6-7 weeks postoperatively. 
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       The aim of this paper was to evaluate regional myocardial function using WMSI. 
However, for completeness, a full echocardiographic examination was done for each patient 
resulting in several more specific measurements. These were included in the article, but we 
were careful to draw conclusions on their basis. Due to a considerable number of 
measurements, the interpretation was prone to type I statistical error, i.e., a false positive 
result. Also, although all patients were considered hemodynamically stable at the time of 
examination, different loading conditions postoperatively could potentially contribute to 
transient changes in volumes or diameters93.  
The most widely used parameter of myocardial systolic function is the LVEF, which is 
calculated as stroke volume divided by the end-diastolic volume94. We found that LVEF was 
significantly reduced between the examinations preoperatively and 6-7 weeks postoperatively. 
The discrepancy between this decrease in global functioning and the simultaneous increase in 
WMSI is difficult to explain. However, a limitation of LVEF detection by echocardiography 
is that the biplane Simpson`s method is dependent on good endocardial border definition. 
Because LVEF measures volume changes secondary to myocardial contraction, it is not a 
direct measure of myocardial function as compared to WMSI. Furthermore, since all 16 
segments contributing to the WMSI were analyzed independently and from multiple 
projections, this is likely to give a more robust assessment than LVEF. WMSI has been 
validated as a prognostic indicator after myocardial infarction showing results superior to 
LVEF95-97. Yet, both WMSI and LVEF are limited by the subjective assessment of the 
examiner.   
Our study is limited by the sample size, and our results need confirmation from larger 
studies. The major limitation of this study is the lack of viability testing preoperatively. 
Improvement in systolic wall thickening postoperatively does strongly suggest the presence of 
viable segments preoperatively, but viability imaging with stress echocardiography could 
have validated this and estimated the number of viable segments preoperatively. Postoperative 
angiography to validate graft status and the success of the revascularization procedure would 
also have been an advantage.  
 
Paper III 
Left ventricular hypertrophy and revascularization 
Our main finding was that higher LVH during anti-hypertensive treatment was independently 
associated with increased incidence of both coronary and peripheral revascularization. That 
33 
 
reduction of LVH is associated with less coronary revascularization seems biologically 
plausible because less myocardial tissue per vessel may decrease myocardial oxygen demand 
and thereby cause less angina pectoris symptoms. It has been reported that coronary flow 
reserve, i.e., the ratio of maximum to basal coronary flow, is impaired in the presence of 
LVH98. A study assessing coronary flow reserve in patients with aortic stenosis before and 
after aortic valve replacement found that coronary flow reserve increased after the operation, 
simultaneously with regression of LVH99. This suggests an association between regression of 
LVH and increase in coronary flow reserve. The exact mechanism of how LVH is related to 
peripheral revascularization is unknown, but as LVH is associated with atherosclerosis, 
endothelial dysfunction and systemic inflammation46,100,101 it may be likely that patients with 
high LVH have more persistent peripheral structural vascular hypertrophy leading to more 
peripheral revascularization.  
      We found that the methods used for detecting LVH had different predictive abilities. 
High Sokolow-Lyon voltage was a significant predictor for revascularization, whereas Cornell 
voltage-duration product was not. We cannot explain this pathophysiologically. It may owe to 
different patient characteristics at baseline dependent on LVH classification by Sokolow-
Lyon voltage or Cornell product. We know that patients with LVH defined by Sokolow-Lyon 
voltage were younger and leaner and had higher pulse pressure and HDL-cholesterol 
compared with patients without LVH with this method102. On the other hand, patients 
recruited by the Cornell criteria in the LIFE study had more metabolic risk factors and greater 
co-morbidity, possibly making them less suitable for invasive procedures. In a study of 2,461 
patients with coronary heart disease only 37% of those with echocardiographically evidence 
of LVH underwent revascularization compared to 51% without LVH, although the patients 
with LVH had more three-vessel disease than the patients without LVH103. Similarly, 
Westerhout et al104 found that cardiac catheterization and PCI procedures occurred less often 
in patients with LVH defined by electrocardiographic Cornell criteria, possibly because LVH 
patients were older with more co-morbidities. This supports the fact that revascularization 
procedures are influenced by other factors than the patients` disease burden, among them 
patients` co-morbidities.   
 
Urine albumin-to-creatinine ratio and revascularization 
We found no effect of regression of urine albumin-to-creatinine ratio on the incidence of 
revascularization. This was unexpected, because several other studies have found a relation 
between albuminuria and cardiovascular disease. The PREVEND study demonstrated that 
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microalbuminuria was independently associated with coronary heart disease, but not 
peripheral artery disease in the general population105. In the same cohort, albuminuria was 
found to significantly add information to the traditional risk factors for predicting the 
composite endpoint of cardiovascular disease which included revascularization procedures106. 
Ibsen et al54 found that reductions in albuminuria translated to reductions in the composite end 
point in the LIFE study. The lack of association between reductions of urine albumin-to-
creatinine ratio and revascularization in our study might reflect that patients without reduction 
in urine albumin-to-creatinine ratio had more generalized atherosclerotic disease and were 
therefore not candidates for revascularization. Another possibility is that this owes to a 
statistical type II error.  
 
Cardiovascular mortality after revascularization 
After revascularization (either coronary or peripheral) we found that continuing LVH by 
Cornell product was a significant predictor of cardiovascular death. Interestingly, continuing 
LVH by Sokolow-Lyon had no significant effect in this setting. This may owe to low 
statistical power because there was a lower prevalence of LVH by this criterion than by 
Cornell product criteria. Another hypothesis, which requires further studies, is that LVH 
assessed by Cornell product is associated with increased cardiovascular mortality by other 
mechanisms than coronary atherosclerosis. Several studies have shown that patients with 
LVH have increased in-hospital and long-term mortality after CABG surgery107-109. Taken 
together with our findings, this suggests that LVH regression should be an independent goal 
in the future therapy and follow-up after revascularization procedures. 
 
Paper IV 
Postoperative CK-MB and cTnT and mortality after CABG 
We found that cTnT is a better predictor than CK-MB of long-term all-cause mortality after 
CABG. Few previous studies have investigated and compared the predictive value of 
troponins and CK-MB in regard to mortality after CABG. Januzzi et al110 found that cTnT 
was superior to CK-MB for predicting in hospital complications after CABG with or without 
combined valve surgery. Similarly, Kathiresan et al111 documented that cTnT was the 
strongest predictor of 1-year mortality, whereas CK-MB added no independent information. 
Vikenes et al112 reported on the effect of cTnI, cTnT and CK-MB in low-risk CABG patients 
with a long-term follow-up of median 7.7 years. CK-MB was superior to the cardiac troponins 
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in predicting long-term event-free survival after elective cardiac surgery. However, only 156 
isolated CABG patients were included in this study. Muehlschlegel et al113 compared the 
biomarkers CK-MB and cTnI and found that cTnI was more robust in predicting mortality 
with a mean follow-up of 3.3 years, in line with our findings. Interestingly, ECG analyses in 
the same study revealed that ECG diagnosis of perioperative myocardial infarction did not 
independently predict an increased risk of mortality or hospital length of stay. The authors 
therefore recommend the use of troponin screening after CABG and suggest that ECG should 
not be used in diagnosing perioperative myocardial infarction. Our findings of superiority of 
cTnT have been supported by two recent studies showing that cardiac troponin I was better 
than CK-MB for quantifying myocyte necrosis as assessed by magnetic resonance imaging 
after CABG114,115 .       
The finding that cTnT was a better predictor of mortality than CK-MB was consistent 
when analyzing the biomarkers as continuous variables, quartiles and also as groups based on 
clinical cut-off values116. The latter analysis was omitted from the published article as the 
American Heart Journal found these less objective than the strict quartile analysis (Figure 5). 
This is an interesting point of discussion because the clinical cut-off values without doubt 
have more relevance for clinicians in the hospital setting. Also, biomarker cut-off values 
defined as five times upper limit of normal are used in the current guidelines defining 
myocardial infarction post-CABG40.  
The pathophysiology behind the association between small leakages of troponins and 
increased mortality after CABG is unknown and most likely multifactorial. However, the 
same relationships are found after PCI117, noncardiac surgery118 and in the general 
population119. This indicates common underlying mechanisms and is interesting as the effect 
is found at time points long after the initiating stimulus. A recent study of nearly 10,000 
individuals from a general population without known coronary heart disease or stroke found 
that even minimally elevated cTnT (0.003 μg/L) was independently associated with 
increased risk for mortality and heart failure120. Of note, cTnT was stronger associated with 
death and heart failure than coronary heart disease, suggesting that other factors than ischemia 
may contribute to the risk associated with cTnT. Other potential causes for troponin release 
from cardiac myocytes may be apoptosis, subclinical structural or functional abnormalities or 
coronary microvascular dysfunction, which occurs in hypertension, diabetes mellitus and left 
ventricular hypertrophy121. Cardiac troponin release has traditionally been associated with 
cardiomyocyte necrosis. However, there is some debate about whether troponins also may be 
released in the case of transient ischemia without cell death122,123. 
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Figure 5. CK-MB and cTnT stratified in groups based on clinical cut-off values, in regard to all-





We focused on the peak values of cTnT and CK-MB in our analyses, as these are 
easier to use in a clinical setting. Interestingly, the biomarker values at 44 hours 
postoperatively had a greater prognostic power than the peak value, suggesting that routine 
biomarker sampling should continue for at least 44 hours. Some studies recommend that 
biomarkers should be measured even longer, until 48 hours or 72 hours postoperatively124,125. 
After CABG, risk stratification of patients to optimize further treatment is important 
both in the acute and in the long-term setting126. Cardiac biomarkers have been proposed as a 
tool for predicting outcomes after cardiac surgery and assisting in decision-making about 
therapeutic interventions. An interesting debate is whether postoperative biomarkers could be 
incorporated into the EuroSCORE or whether they have sufficient power to function as 
independent risk stratification markers. According to a study by Fellahi et al127, the 
combination of EuroSCORE and postoperative cTnI provides the best discriminative power 
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for predicting adverse outcome after cardiac surgery, and this combination was suggested as 
being an effective model that improves early identification of high-risk patients.   
 The large size of our study population allowed us to adjust for a number of potential 
confounders. However, we cannot exclude the effect of potential other, yet unknown, 
confounders that may cause biomarker elevation and contribute to long-term mortality. 
Importantly, this is a single-center study and multi-center studies with a greater number of 





The global burden of coronary artery disease is expected to continue increasing and 
consequently also the use of CABG worldwide in the foreseeable future. This justifies further 
research within this area of cardiac surgery, to ensure optimal postoperative care. Our study 
dealt with the changes of myocardial function up to 6-7 weeks after CABG using myocardial 
perfusion scintigraphy and echocardiography. In the ten years since this study was initiated, 
several newer imaging modalities have become available and it would be of value to perform 
larger studies using magnetic resonance imaging and strain imaging to obtain an even better 
understanding of changes in myocardial function and the changes induced in hibernating 
myocytes early after CABG.  
Regarding the diagnosis of perioperative myocardial infarction, larger studies with 
coronary angiography performed postoperatively are needed to verify which thresholds of 
cardiac biomarkers are diagnostic. Nevertheless, we doubt that strict criteria will be of value 
in the clinical setting. It seems impossible to set a certain threshold for the level of markers 
that may not be explained by the CABG procedure itself. Perhaps implementing the use of 
echocardiography or other imaging modalities as a routine postoperatively for patients with 
biomarkers above a certain level could be an effective diagnostic tool for perioperative 
myocardial infarction.      
Our findings in this thesis point out the independent effects of continuing LVH in the 
ECG and high postoperative biomarker levels on survival after revascularization. Currently, 
the prognostic influence is not addressed in the guidelines. The results of our multivariate 
analyses are hypothesis generating and should be validated in prospective studies. It would be 
interesting to study whether a more intensive follow-up schedule after CABG with emphasis 
on implementing evidence-based medical therapy for patients with elevated postoperative 







Myocardial perfusion at rest improved 2-4 days after CABG and no further changes in 
perfusion were observed during the following six weeks. We could not detect more cases of 
perioperative myocardial infarction using myocardial perfusion scintigraphy compared with 
the use of ECG and cardiac biochemical markers.    
 
Paper II 
There was a gradual improvement of left ventricular contractile function at rest determined by 
the wall motion score index during the first 6-7 weeks after CABG, suggesting the presence 
of hibernating myocardium.  
 
Paper III 
Lack of regression of Sokolow-Lyon voltage was associated with higher incidence of 
coronary as well as peripheral revascularization. Regression of urine albumin-to-creatinine 
ratio was not associated with revascularization. After revascularization, continuing LVH by 
Cornell voltage-duration product was associated with cardiovascular death. Our data 
emphasize the importance of measuring LVH in hypertensive patients.  
 
Paper IV 
Both CK-MB and cTnT were predictors of long-term mortality after CABG. However, CK-
MB did not provide independent prognostic information when analyzed together with cTnT. 
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